Neurology

March is MS awareness month, spotlighting this chronic, progressive disease that is growing in prevalence.

The gut microbiome may play a key role impact the severity of multiple sclerosis symptoms.

Deep transcranial stimulation could provide more relief from fatigue among multiple sclerosis patients compared with other treatments.

A popular multiple sclerosis drug may increase the risk of a potentially-fatal brain infection.

Less serious adverse events remain a concern for patients treated for chronic diseases.

Balance and eye movement exercise improved quality of life for patients with multiple sclerosis.

Officials with the FDA have approved Novartis' glatiramer acetate injection (Glatopa) 40-mg/mL for the treatment of multiple sclerosis (MS).

A cytokine may protect myelin against attacks by the immune system in multiple sclerosis.

A number of landmark clinical studies in the field of MS have been published, shaping how the disease is treated.

The RAISE Family Caregivers Act aids individuals taking care of loved ones with chronic diseases.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

A multiple sclerosis drug may be used as a PET scan tracer agent to image demyelination.

Controlling cholesterol synthesis expression may reduce walking disability in patients with multiple sclerosis.

A number of landmark clinical studies in the field of MS have been published, shaping how the disease is treated.

An investigational immunotherapy for multiple sclerosis targets Epstein-Barr virus.

A panel of multiple sclerosis experts recently modified the 2010 McDonald Criteria to improve the diagnostic process.

Estrogen produced during pregnancy could reduce multiple sclerosis relapses by 70%.

Taurine may increase the remyelination effects of multiple sclerosis treatments.

A look back at the top articles of the year on Specialty Pharmacy Times.

The market for disease-modifying multiple sclerosis drugs is projected to reach $25.3 billion by 2026, according to a new report.

Significant opportunities exist for the development of new drugs for relapsing remitting multiple sclerosis.

Human Vaccines Project seeks to decode the human immune system to facilitate accelerated development of diagnostics, vaccines and therapies for major global diseases.

Fingolimod was previously approved to treat relapsing multiple sclerosis as a once-daily disease-modifying therapy.

Disrupting the circadian rhythm exacerbate multiple sclerosis symptoms.